BS_FAQQ0GCQ
Ganglioglioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Ganglioglioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Ganglioglioma
- overall_survival_months
- 25.689881734559787
- age_years
- 19.855
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_55JW3HFM | Ganglioglioma | — | 0.911 |
| 2 | BS_X91K8KMG | pilocytic astrocytoma | — | 0.893 |
| 3 | BS_MF9X3PKH | low-grade glioma | — | 0.888 |
| 4 | BS_HX0S30NE | pilocytic astrocytoma | — | 0.887 |
| 5 | BS_Z7Y2466H | pilocytic astrocytoma | — | 0.884 |
| 6 | BS_E94QRJDW | low-grade glioma | — | 0.884 |
| 7 | BS_F8N6CFQE | low-grade glioma | — | 0.875 |
| 8 | BS_7Z93ZYMS | pilocytic astrocytoma | — | 0.871 |
| 9 | BS_014EVM2D | low-grade glioma | — | 0.871 |
| 10 | ERR2598287 | fetal | fetal | 0.870 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.581 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.560 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.541 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.515 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.507 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.443 | Inavolisib | — uncovered |
| COAGULATION | 0.430 | Binimetinib | — uncovered |
| COMPLEMENT | 0.429 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.427 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.402 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.378 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.364 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.346 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.344 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.313 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.295 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.271 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.252 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.235 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.219 | Inavolisib | — uncovered |